202
Participants
Start Date
September 9, 2019
Primary Completion Date
December 15, 2022
Study Completion Date
July 28, 2025
FEDRATINIB
A potent and selective inhibitor of JAK2 kinase activity
Best Available Therapy (BAT)
Best available therapy (BAT)
Local Institution - 557, Zhengzhou
Local Institution - 600, Budapest
Local Institution - 150, Vienna
Local Institution - 152, Vienna
Local Institution - 202, Brussels
Local Institution - 103, Darlinghurst
Local Institution - 201, Leuven
Local Institution - 100, Melbourne
Local Institution - 904, Seoul
Local Institution - 105, Box Hill
Local Institution - 102, Langwarrin
Local Institution - 204, Liège
Local Institution - 155, Linz
Local Institution - 604, Nyíregyháza
Local Institution - 153, Wels
Local Institution - 101, Adelaide
Local Institution - 151, Salzburg
Local Institution - 902, Seoul
Local Institution - 203, Yvoir
Local Institution - 154, Innsbruck
Local Institution - 603, Szeged
Local Institution - 205, La Louvière-(Haine St-Paul)
Local Institution - 602, Kaposvár
Local Institution - 200, Bruges
Local Institution - 452, Badalona (Barcelona)
Local Institution - 601, Győr
Local Institution - 355, Torino
Local Institution - 900, Seongnam-si
Local Institution - 460, Santiago de Compostela
Local Institution - 462, Girona
Local Institution - 358, Milan
Local Institution - 352, Varese
Local Institution - 363, Brescia
Local Institution - 357, Pavia
Local Institution - 453, Madrid
Local Institution - 459, Madrid
Local Institution - 457, Málaga
Local Institution - 256, Brest
Local Institution - 454, Murcia
Local Institution - 250, Nîmes
Local Institution - 253, Toulouse
Local Institution - 304, Minden
Local Institution - 360, Udine
Local Institution - 258, Pessac
Local Institution - 461, Las Palmas de Gran Canaria
Local Institution - 455, Salamanca
Local Institution - 364, Verona
Local Institution - 463, Santa Cruz de Tenerife
Local Institution - 307, Magdeburg
Local Institution - 353, Bologna
Local Institution - 456, Valencia
Local Institution - 458, Barakaldo
Local Institution - 255, Angers
Local Institution - 350, Florence
Local Institution - 302, Aachen
Local Institution - 259, Lille
Local Institution - 308, Frankfurt am Main
Local Institution - 254, Lens
Local Institution - 251, Strasbourg
Local Institution - 301, Mannheim
Local Institution - 257, Pierre-Bénite
Local Institution - 156, Graz
Local Institution - 252, Paris
Local Institution - 362, Naples
Local Institution - 261, Poitiers
Local Institution - 305, Ulm
Local Institution - 354, Catania
Local Institution - 555, Beijing
Local Institution - 855, Moscow
Local Institution - 851, Moscow
Local Institution - 853, Moscow
Local Institution - 852, Saint Petersburg
Local Institution - 854, Saint Petersburg
Local Institution - 850, Saint Petersburg
Local Institution - 553, Tianjin
Local Institution - 859, Vladikavkaz
Local Institution - 550, Guangzhou, Guangdong
Local Institution - 857, Novosibirsk
Local Institution - 700, Brno
Local Institution - 702, Ostrava-Poruba
Local Institution - 701, Prague
Local Institution - 260, Nice
Local Institution - 306, Halle
Local Institution - 303, Jena
Local Institution - 751, Cork
Local Institution - 752, Dublin
Local Institution - 750, Dublin
Local Institution - 356, Roma
Local Institution - 361, Roma
Local Institution - 359, Roma
Local Institution - 402, Maastricht
Local Institution - 400, Nijmegen
Local Institution - 803, Poznan
Local Institution - 801, Warsaw
Local Institution - 802, Wroclaw
Local Institution - 905, Seoul
Local Institution - 901, Seoul
Local Institution - 903, Seoul
Local Institution - 451, Alicante
Local Institution - 450, Barcelona
Local Institution - 504, Manchester
Local Institution - 506, Nottingham
Local Institution - 502, Birmingham
Local Institution - 503, Boston
Local Institution - 501, London
Local Institution - 505, London
Local Institution - 500, Oxford
Lead Sponsor
Celgene
INDUSTRY
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
INDUSTRY